Literature DB >> 18362158

The "albumin effect" and drug glucuronidation: bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities.

Andrew Rowland1, Kathleen M Knights, Peter I Mackenzie, John O Miners.   

Abstract

Bovine serum albumin (BSA) and fatty acid-free human serum albumin (HSAFAF) reduce the K(m) values for UGT2B7 substrates by sequestering inhibitory long-chain fatty acids released by incubations of human liver microsomes (HLM) and HEK293 cells expressing this enzyme. However, the scope of the "albumin effect" is unknown. In this investigation we characterized the effects of albumin on the kinetics of 4-methylumbelliferone (4MU) glucuronidation by UDP-glucuronosyltransferase (UGT) 1A1, 1A6, and 1A9, and propofol (PRO) glucuronidation by UGT1A9 and HLM. BSA and HSAFAF, but not human serum albumin, reduced the K(m) values for 4MU and PRO glucuronidation by UGT1A9. For example, HSAFAF (2%) reduced the K(m) values for 4MU and PRO glucuronidation from 13.4 to 2.9 and 41 to 7.2 microM, respectively. Similarly, HSAFAF (2%) reduced the K(m) for PRO glucuronidation by HLM from 127 to 10.6 muM. Arachidonic, linoleic, and oleic acids and a mixture of these decreased the rates of 4MU and PRO glucuronidation by UGT1A9. K(m) values for these reactions were increased 3- to 6-fold by the fatty acid mixture. Inhibition was reversed by the addition of BSA (2%). Extrapolation of kinetic constants for PRO glucuronidation by HLM in the presence of HSAFAF predicted in vivo hepatic clearance within 15%. Fatty acids had no effect on 4MU glucuronidation by UGT1A1 and UGT1A6 but, paradoxically, all forms of albumin altered the kinetic model for 4MU glucuronidation by UGT1A6 (from Michaelis-Menten to two-site). Only BSA caused a similar effect on 4MU glucuronidation by UGT1A1. It is concluded that BSA and HSAFAF reduce the K(m) values of only those enzymes inhibited by long-chain unsaturated fatty acids.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18362158     DOI: 10.1124/dmd.108.021105

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  33 in total

1.  Chemoenzymatic Synthesis, Characterization, and Scale-Up of Milk Thistle Flavonolignan Glucuronides.

Authors:  Brandon T Gufford; Tyler N Graf; Noemi D Paguigan; Nicholas H Oberlies; Mary F Paine
Journal:  Drug Metab Dispos       Date:  2015-08-27       Impact factor: 3.922

2.  Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.

Authors:  Katherine L Gill; J Brian Houston; Aleksandra Galetin
Journal:  Drug Metab Dispos       Date:  2012-01-24       Impact factor: 3.922

3.  Metabolic pathways of the camptothecin analog AR-67.

Authors:  Jamie Horn; Marta Milewska; Susanne M Arnold; Markos Leggas
Journal:  Drug Metab Dispos       Date:  2010-12-28       Impact factor: 3.922

4.  Inhibition of human drug-metabolising cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in vitro by uremic toxins.

Authors:  Kyra J Barnes; Andrew Rowland; Thomas M Polasek; John O Miners
Journal:  Eur J Clin Pharmacol       Date:  2014-06-24       Impact factor: 2.953

Review 5.  Challenges and Opportunities with Non-CYP Enzymes Aldehyde Oxidase, Carboxylesterase, and UDP-Glucuronosyltransferase: Focus on Reaction Phenotyping and Prediction of Human Clearance.

Authors:  Upendra A Argikar; Philip M Potter; J Matthew Hutzler; Punit H Marathe
Journal:  AAPS J       Date:  2016-08-05       Impact factor: 4.009

6.  Enzyme Kinetics of Uridine Diphosphate Glucuronosyltransferases (UGTs).

Authors:  Jin Zhou; Upendra A Argikar; John O Miners
Journal:  Methods Mol Biol       Date:  2021

7.  Consideration of the Unbound Drug Concentration in Enzyme Kinetics.

Authors:  Nigel J Waters; R Scott Obach; Li Di
Journal:  Methods Mol Biol       Date:  2021

8.  Prediction of Drug Clearance from Enzyme and Transporter Kinetics.

Authors:  Priyanka R Kulkarni; Amir S Youssef; Aneesh A Argikar
Journal:  Methods Mol Biol       Date:  2021

9.  Obstetric Obesity is Associated with Neonatal Hyperbilirubinemia with High Prevalence in Native Hawaiians and Pacific Island Women.

Authors:  Luc Ra Rougée; Shogo J Miyagi; Abby C Collier
Journal:  Hawaii J Med Public Health       Date:  2016-12

10.  Relative importance of intestinal and hepatic glucuronidation-impact on the prediction of drug clearance.

Authors:  Helen E Cubitt; J Brian Houston; Aleksandra Galetin
Journal:  Pharm Res       Date:  2009-01-31       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.